Trial · NCT03485976
Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
NCT03485976, Phase 2, Completed, Oregon Health and Science University; results first posted 2020-07-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP). Trials, record NCT03485976. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03485976
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
- NCT number
- NCT03485976
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Oregon Health and Science University
- Conditions
- Pityriasis Rubra Pilaris
- Interventions
- Ixekizumab
- First posted
- 2018-04-03
- Last updated
- 2020-07-01
- Results first posted
- 2020-07-01
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Improvement in PRP Severity and Body Surface Area | 24 weeks | Clinical improvement will be measured by the Psoriasis Area and Severity Index (PASI) score. PASI is a scale that measures the severity (redness, scale, and elevation) of each body surface area of skin involved in psoriasis (a disease that has some similarities with PRP). Redness, scale, and elevation are each scored on a 0-4 point scale, added together, and multiplied by each body surface area involved (head and neck, trunk, upper limbs, lower limbs). The maximum score is 72 which would indicate the worst disease over every surface of someone's body. A scale of zero would indicate normal skin. |
| Secondary | Improvement in Quality of Life | 24 weeks | Quality of life will be measured by the Dermatology Life Quality Index (DLQI). There are 10 questions covering symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question refers to the impact of PRP on the patient's life over the previous week. The highest score is 30 and would indicate a maximum (negative) impact on quality of life. A score of zero would indicate no impact on quality of life. |
| Secondary | Improvement in Itch | 24 weeks | Itch will be measured using a numeric rating scale from 0 (no itch) to 10 (worst itch imaginable). |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Clinical Improvement in PRP Severity and Body Surface Area | 24 weeks | Mean improvement in PASI from baseline to week-24 | units on a scale | MEAN |
| SECONDARY | Improvement in Quality of Life | 24 weeks | units on a scale | MEAN | |
| SECONDARY | Improvement in Itch | 24 weeks | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Improvement in PRP Severity and Body Surface Area | Ixekizumab Treatment Arm | 15.2 | Standard Error 2.1 | units on a scale | |
| Improvement in Quality of Life | Ixekizumab Treatment Arm | 9.5 | Standard Error 2.5 | units on a scale | |
| Improvement in Itch | Ixekizumab Treatment Arm | 3.6 | Standard Error 0.8 | units on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ixekizumab Treatment Arm | 12 | |
| Overall Study | COMPLETED | Ixekizumab Treatment Arm | 11 | |
| Overall Study | NOT COMPLETED | Ixekizumab Treatment Arm | 1 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper respiratory tract infection | Infections and infestations | Ixekizumab Treatment Arm | 4 | 12 | 4 |
| other | Gastrointestinal upset | Gastrointestinal disorders | Ixekizumab Treatment Arm | 1 | 12 | 1 |
| other | Injection site reaction | Skin and subcutaneous tissue disorders | Ixekizumab Treatment Arm | 1 | 12 | 1 |
| other | Temporary worsening of PRP | Skin and subcutaneous tissue disorders | Ixekizumab Treatment Arm | 1 | 12 | 1 |
| other | Otitis externa | Infections and infestations | Ixekizumab Treatment Arm | 1 | 12 | 1 |
| other | Ingrown nail | Skin and subcutaneous tissue disorders | Ixekizumab Treatment Arm | 1 | 12 | 1 |
| other | Glaucoma | Eye disorders | Ixekizumab Treatment Arm | 1 | 12 | 1 |
| other | Non-specific chest pain (resolved without intervention) | Cardiac disorders | Ixekizumab Treatment Arm | 1 | 12 | 1 |
| other | Mild leukopenia | Blood and lymphatic system disorders | Ixekizumab Treatment Arm | 1 | 12 | 1 |
| other | Eosinophilia | Blood and lymphatic system disorders | Ixekizumab Treatment Arm | 1 | 12 | 1 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ixekizumab Treatment Arm | 0 | 12 |
| Total, other adverse events | Ixekizumab Treatment Arm | 8 | 12 |
| Total, serious adverse events | Ixekizumab Treatment Arm | 0 | 12 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32293641 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03485976
GET https://conductscience.org/api/trials/v1/NCT03485976/registered